[SYN] Synthetic Biologics, Inc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 0.85 Change: 0.03 (4.17%)
Ext. hours: Change: 0 (0%)

chart SYN

Refresh chart

Strongest Trends Summary For SYN

SYN is in the medium-term down -25% below S&P in 5 months and down -95% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Synthetics Biologics, Inc., a biotechnology company, focuses on development of novel anti-infective biologics and drug candidates targeting specific pathogens that cause serious infections and other diseases. The company?s product candidates include Trimesta, which has completed phase II clinical trials for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis; SYN-010 that is in preclinical stage for the treatment of constipation-predominant irritable bowel syndrome; SYN-004, which is in preclinical stage for the treatment of clostridium difficile infection prevention; SYN-005 that is in preclinical stage for the treatment of pertussis; SYN-001, which is in discovery stage for the treatment of acinetobacter infection; and SYN-007 that is in discovery stage for the treatment of irritable bowel syndrome. It has a sublicense agreement with Meda AB for the development and commercialization of Effirma (flupirtine) for fibromyalgia in the United States, Canada, and

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y60.54% Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-206.36% ROE1741.78% ROI
Current Ratio0.89 Quick Ratio Long Term Debt/Equity Debt Ratio-9.44
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities-20 K Gross Profit
Net Profit-5.46 M Operating Profit-8.21 M Total Assets13.72 M Total Current Assets13.62 M
Total Current Liabilities15.34 M Total Debt Total Liabilities15.34 M Total Revenue
Technical Data
High 52 week12.93 Low 52 week0.3 Last close0.67 Last change2.27%
RSI55.81 Average true range0.03 Beta0.53 Volume439.69 K
Simple moving average 20 days4.06% Simple moving average 50 days5.86% Simple moving average 200 days-80.12%
Performance Data
Performance Week7.58% Performance Month6.35% Performance Quart-12.43% Performance Half-77.29%
Performance Year71.64% Performance Year-to-date19.63% Volatility daily2.53% Volatility weekly5.66%
Volatility monthly11.61% Volatility yearly40.21% Relative Volume277% Average Volume294.39 K
New High New Low

News

2019-02-28 02:58:59 | Edited Transcript of SYN earnings conference call or presentation 27-Feb-19 9:30pm GMT

2019-02-27 16:10:00 | Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results

2019-02-27 15:05:03 | Sýn hf. : Q4 Investors presentation

2019-02-27 14:55:04 | Sýn hf. : Changes in management of Sýn hf.

2019-02-27 14:53:00 | Sýn hf. : Merged company completes its first full year under challenging market conditions

2019-02-26 10:38:01 | Sýn hf. : Sýn finalizes the merger of Hey P/F with Nema P/F

2019-02-19 16:30:00 | Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019

2019-01-03 07:00:00 | Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored

2018-12-04 12:00:00 | Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer

2018-11-27 08:20:00 | Report: Exploring Fundamental Drivers Behind Synthetic Biologics, Plexus, TG Therapeutics, Hortonworks, NorthWestern, and Archer Daniels Midland — New Horizons, Emerging Trends, and Upcoming Developments

2018-11-22 09:10:02 | New Trends in Healthcare Push Stocks Higher: 5 Picks

2018-11-21 09:25:00 | New Healthcare Trends Could Push Sector Stocks Higher

2018-11-21 07:00:00 | Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 ribaxamase Development

2018-11-09 01:17:04 | Edited Transcript of SYN earnings conference call or presentation 8-Nov-18 9:30pm GMT

2018-11-08 18:02:57 | Synthetic Biologics: 3Q Earnings Snapshot

2018-11-08 16:10:00 | Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results

2018-10-30 16:30:00 | Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018

2018-10-18 08:40:54 | Does Synthetic Biologics Inc NYSEMKT:SYN Have A High Beta?

2018-10-15 13:30:00 | Synthetic Biologics Announces Closing of $18,639,000 Public Offering

2018-10-12 07:35:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Hyatt Hotels, E.W. Scripps, Cardtronics, Lincoln National, Synthetic Biologics, and Herc — New Research Emphasizes Economic Growth

2018-10-11 09:07:00 | Synthetic Biologics Prices $18,000,000 Public Offering

2018-09-30 09:26:06 | Who Are The Major Shareholders Of Synthetic Biologics Inc NYSEMKT:SYN?

2018-09-06 07:00:00 | Synthetic Biologics Announces Agreement with Cedars-Sinai Medical Center for an Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C

2018-08-30 16:10:00 | Synthetic Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

2018-08-22 21:55:24 | Edited Transcript of SYN earnings conference call or presentation 8-Aug-18 8:30pm GMT

2018-08-17 14:32:59 | What Goes Through The Mind of A Trader When Taking A Position?

2018-08-13 07:55:00 | Consolidated Research: 2018 Summary Expectations for Fulton Financial, Leidos, Principal Financial Group, Quanta Services, Synthetic Biologics, and Sterling — Fundamental Analysis, Key Performance Indications

2018-08-08 17:31:53 | Synthetic Biologics: 2Q Earnings Snapshot

2018-08-08 16:10:00 | Synthetic Biologics Reports Second Quarter 2018 Operational Highlights and Financial Results

2018-08-08 14:30:00 | Synthetic Biologics, Inc. to Host Earnings Call

2018-08-08 12:27:48 | Is Now The Time To Bet On The Healthcare Sector And Synthetic Biologics Inc NYSEMKT:SYN?

2018-08-01 17:05:00 | Synthetic Biologics Announces Reverse Stock Split

2018-07-31 07:00:00 | Synthetic Biologics to Report Second Quarter 2018 Operational Highlights and Financial Results on August 8, 2018

2018-06-20 07:50:00 | Stock Performance Review on Sesen Bio and Three Other Biotech

2018-05-22 07:00:00 | Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American

2018-05-21 07:25:00 | Stock Performance Review on Tesaro and Three Other Biotech Industry

2018-05-14 07:40:00 | Report: Developing Opportunities within Crown, American Equity Investment Life Holding, Acco Brands, Synthetic Biologics, Universal Display, and Lamb Weston — Future Expectations, Projections Moving into 2018

2018-05-09 07:48:14 | Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

2018-05-09 05:11:09 | Synthetic Biologics: 1Q Earnings Snapshot

2018-05-08 19:46:01 | Edited Transcript of SYN earnings conference call or presentation 8-May-18 8:30pm GMT

2018-05-08 16:05:00 | Synthetic Biologics Reports First Quarter 2018 Operational Highlights and Financial Results

2018-04-26 07:00:00 | Synthetic Biologics to Report First Quarter 2018 Operational Highlights and Financial Results on May 8, 2018

2018-04-23 07:00:00 | Synthetic Biologics Provides Update on Development of SYN-004 ribaxamase, for the Prevention of C. difficile Infection

2018-03-09 08:25:00 | Report: Exploring Fundamental Drivers Behind EOG Resources, Alteryx, Synthetic Biologics, Extreme Networks, Knight-Swift Transportation Holdings Inc., and Select Medical — New Horizons, Emerging Trends, and Upcoming Developments

2018-03-07 16:10:00 | Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan

2018-02-22 20:21:13 | Edited Transcript of SYN earnings conference call or presentation 22-Feb-18 1:30pm GMT

2018-02-22 06:47:00 | Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results

2018-02-22 06:20:00 | Synthetic Biologics, Inc. to Host Earnings Call

2018-02-15 16:10:00 | Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018

2018-01-02 16:30:00 | Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference